The Fixed Combination of Valerian and Hops (Ze91019) acts via a Central Adenosine Mechanism

Abstract

The aim of the study was to demonstrate competition between caffeine and a fixed valerian/hop extract combination (Ze91019) by the central adenosine mechanism. EEG was used to describe the action of caffeine on the central nervous system after oral administration (200 mg) in healthy volunteers. In addition to caffeine, the volunteers (16 in each group) received either placebo or verum (2 and 6 tablets containing the valerian/hop extract). The EEG responses were recorded every 30 min thereafter. The verum medication was capable of reducing (2 tablets) or inhibiting (6 tablets) the arousal induced by caffeine. This pharmacodynamic action was observed 60 minutes after oral administration, indicating not only competition between the antagonist caffeine and the partial agonist, i. e., the valerian/hop extract but also bio-availability of the compound(s) responsible for the agonistic action. In conclusion, the valerian/hop extract acts via a central adenosine mechanism which is possibly the reason for its sleep-inducing and -maintaining activity.

Key words

Valerian-hop-extract-combination - interaction - caffeine - EEG - Valeriana officinalis - Valerianaceae - Humulus lupulus - Cannabaceae

References

• 1 Vonderheid-Guth B, Todorova A, Brattström A, Dimpfel W. Pharmacodynamic effects of valerian and hops extract combination (Ze91019) on the quantitative-topographical EEG in healthy volunteers.  Eur J Med Res. 2000;  5 139-44
• 2 Rodenbeck A, Simen S, Cohrs S, Jordan W Kinkelbur J, Staedt J, Hajak G. Veränderte Schlafstadienstruktur als Hinweis auf die GABAerge Wirkung eines Baldrian-Hopfenpräparates bei Patienten mit psychophysiologischer Insomnie.  Somnologie. 1998;  2 26-31
• 3 Füssel A, Wolf A, Brattström A. Effect of a fixed valerian-hop extract combination (Ze91019) on sleep polygraphy in patients with non-organic insomnia: a pilot study.  Eur J Med Res. 2000;  5 385-90
• 4 Basheer R, Porkka-Heiskanen T, Strecker R E, Thakkar M M, McCarley R W. Adenosine as a biological signal mediating sleepiness following prolonged wakefulness.  Biological Signals and Receptors. 2000;  9 319-27
• 5 Strecker R E, Morairty S, Thakkar M M, Porkka-Heiskanen T, Basheer R, Dauphin L, Rainnie D G, Portas C M, Greene R W, McCarley R W. Adenosinergic modulation of basal forebraisn and preoptic/anterior hypothalamic neuronal activity in the control of behavioral state.  Behavioural Brain Res. 2000;  115 183-204
• 6 Basheer R, Galldner L, Alanko L, McCarley R W, Fredholm B B, Porkka-Heiskanen T. Opposite changes in andenosine A₁ and A_2A receptor mRNA in the rat following sleep deprivation.  Sleep. 2001;  12 1577-80
• 7 Balduini W, Cattabeni F. Displacement of [³ H]-N ⁶-cyclohexylandenosine binding to rat cortical membranes by hydroalcoholic extract of Valeriana officinalis .  Med Sci Res. 1989;  17 639-40
• 8 Koetter U, Abourashed E A, Brattström A, Schellenberg R. Effect of a fixed valerian-hops extract combination (Ze 91 019) on quantitative EEG data in healthy subjects with caffeine induced hyper-arousal.  Sleep. 2002;  25 A46
• 9 Müller C E, Schumacher B, Brattström A, Abourashed E A, Koetter U. Interaction of valerian extracts and a fixed valerian-hop extract combination with adenosine receptors.  Life Science. 2002;  71 1939-49
• 10 Schumacher B, Scholle S, Hölzl J, Khudeir N, Hess S, Müller C E. Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A1 adenosine receptors.  J Nat Prod. 2002;  65 1479-85
• 11 Kochmann M, Kunz H. Über die Wirkung des Baldrian und eine Methode der Wertbestimmung.  Arch Exp Path Pharmakol. 1936;  181 421-34
• 12 Haffner F. Die pharmakologische Wertbestimmung des Baldrian.  Münchner Med Wochenschrift. 1929;  7 271-272
• 13 Werz v. R, Homann G. Über die Prüfung von Beruhigungsmitteln am Menschen.  Arch Exp Path Pharmakol. 1939;  193 272-280
• 14 Karacan I, Thornby J I, Anch A M, Booth G H, Williams R L, Salis P J. Dose-related sleep disturbances induced by coffee and caffeine.  Clin Pharmacol Therapeutics. 1977;  20 682-9
• 15 Pollak C P, Bright D. Caffeine consumption and weekly sleep patterns in US seventh-, eighth-, and ninth-graders.  Pediatrics. 2003;  111 42-6
• 16 Schellenberg R, Schwarz A, Knorr W, Haufe C. EEG-brain mapping - a method to optimize therapy in schizophrenics using absolute power and center frequency values.  Schizophrenia Res. 1992;  8 21-9
• 17 Schellenberg R, Todorova A, Dimpfel W, Schober F. Pathophysiology and psychopharmacology of dementia - a new study design. Diagnosis comprising subjective and objective criteria.  Neuropsychobiology. 1985;  32 81-97
• 18 Schellenberg R, Sauer S, Dimpfel W. Pharmacodynamic effects of two different Hypericum extracts in healthy volunteers measured by quantitative EEG.  Pharmacopsychiatry. 1998;  31 44-53
• 19 Dimpfel W, Schober F, Spüler M. The influence of caffeine on human EEG under resting conditions and during mental loads.  Clin Investig. 1993;  71 197-207
• 20 Benowitz N L. Clinical pharmacology of caffeine.  Ann Rev Med. 1990;  41 277-288
• 21 Saletu B, Anderer P, Kinsberger K. et al . Topographic brain mapping of EEG in neuropsychopharmacology. II. Clinical applications (pharmaco EEG imaging).  Methods Find Exp Clin Parmacol. 1987;  9 385-408
• 22 Schulz H, Jobert M, Hübner W G. The quantitative EEG as a screening instrument to identify sedative effects of single doses of plant extracts in comparison with diazepam.  Phytomedicine. 1998;  5 449-58
• 23 Hasenfratz M, Bättig K. Acute dose-effect relationships of caffeine and mental performance, EEG, cardiovascular and subjective parameters.  Psychopharmacology. 1994;  114 281-7